title: Novel spirosuccinimides with incorporated isoindolone and benzisothiazole 1,1-dioxide moieties as aldose reductase inhibitors and antihyperglycemic agents.
abstract: Compounds from two novel series of spirosuccinimides were prepared. Analogs of series 2 possessed a spiro-fused isoindolone moiety while those of series 3 contained a spiro-fused benzisothiazole S,S-dioxide group. These compounds were evaluated as aldose reductase inhibitors (ARI) in vitro by their ability to inhibit glyceraldehyde reduction using a partially purified bovine lens aldose reductase preparation and in vivo as inhibitors of galactitol accumulation in the lens, sciatic nerve, and diaphragm of galactose-fed rats. Many members from the isoindolone series 2, particularly those containing an isoindolone N-methyl moiety, showed good in vitro and in vivo potency. The most potent member, the 6-chloro analog 32, was resolved, and aldose reductase activity was found to reside almost exclusively in the (+)-enantiomer. Compound 32 was approximately equipotent in the sciatic nerve of the galactose-fed rat to other cyclic imide ARI's of similar in vitro activity, namely sorbinil and ADN-138 and also to tolrestat, an acetic acid-based ARI (ED50's 4-8 mg/kg). Compounds from both series, 2 and 3, were also found to lower plasma glucose levels of genetically obese db/db and ob/ob mice with potency similar to that of ciglitazone. However, members from these series failed to lower insulin levels of the ob/ob mouse at the doses tested.
authors: Wyeth-Ayerst Research, Inc., Princeton, New Jersey 08543-8000.
authors: J
authors: J
authors: Wrobel
authors: A
authors: A
authors: Dietrich
authors: S A
authors: SA
authors: Woolson
authors: J
authors: J
authors: Millen
authors: M
authors: M
authors: McCaleb
authors: M C
authors: MC
authors: Harrison
authors: T C
authors: TC
authors: Hohman
authors: J
authors: J
authors: Sredy
authors: D
authors: D
authors: Sullivan
mesh_terms: D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors*; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D002417:Cattle; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000188:drug therapy; D005985:Glyceraldehyde / Q000378:metabolism; D007004:Hypoglycemic Agents / Q000138:chemical synthesis* / Q000494:pharmacology / Q000627:therapeutic use; D007211:Indoles / Q000138:chemical synthesis* / Q000494:pharmacology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D015394:Molecular Structure; D051381:Rats; D013329:Structure-Activity Relationship; D013388:Succinimides / Q000138:chemical synthesis* / Q000494:pharmacology / Q000627:therapeutic use; D013844:Thiazoles / Q000138:chemical synthesis* / Q000494:pharmacology / Q000627:therapeutic use; D045162:Thiazolidinediones
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007211:Indoles; D013388:Succinimides; D013844:Thiazoles; D045162:Thiazolidinediones; D005985:Glyceraldehyde; D000449:Aldehyde Reductase; C039671:ciglitazone